The objective of myopia management is to slow the rate of myopia progression significantly, preferably by 50 percent or more per year. That would achieve the goal of substantially reducing the prevalence of high myopia (-5.00D or greater) by up to 90 percent. To date, topical application of atropine is the only evidence-based drug found effective for myopia management. In comparison to 1 percent (high dose) atropine, low dose atropine is advantageous as there are reduced side effects (photophobia and near blur) while maintaining effective myopia control. Furthermore, the use of topical low-dose atropine for myopia control in children is beginning to be widely adopted after positive results from large scale trials (ATOM2 and LAMP studies) as well as some real-world studies. Read More